Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Work In Process (2016 - 2018)

Sanofi's Work In Process history spans 4 years, with the latest figure at $4.7 billion for Q4 2018.

  • For Q4 2018, Work In Process rose 7.34% year-over-year to $4.7 billion; the TTM value through Dec 2018 reached $4.7 billion, up 7.34%, while the annual FY2018 figure was $4.8 billion, 15.82% up from the prior year.
  • Work In Process for Q4 2018 was $4.7 billion at Sanofi, up from $4.3 billion in the prior quarter.
  • Across five years, Work In Process topped out at $4.7 billion in Q4 2018 and bottomed at $3.8 billion in Q4 2015.
  • The 4-year median for Work In Process is $4.2 billion (2016), against an average of $4.2 billion.
  • The largest annual shift saw Work In Process increased 7.56% in 2016 before it grew 5.89% in 2017.
  • A 4-year view of Work In Process shows it stood at $3.8 billion in 2015, then rose by 7.56% to $4.1 billion in 2016, then rose by 5.89% to $4.3 billion in 2017, then rose by 7.34% to $4.7 billion in 2018.
  • Per Business Quant, the three most recent readings for SNY's Work In Process are $4.7 billion (Q4 2018), $4.3 billion (Q4 2017), and $4.1 billion (Q4 2016).